The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | RIC allogeneic HCT for high-risk MDS
Corey Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the BMT CTN 1102 trial (NCT02016781), comparing reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) to non-transplant therapies in patients aged 50-75 with advanced myelodysplastic syndromes (MDS). The study observed a significant overall survival (OS) advantage in older patients who had Int-2 and high-risk MDS and were RIC HCT candidates with HLA-matched donors, compared to those without a donor. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
